Prophylactic efficacy of BeneFIX vs Alprolix in hemophilia B mice

Blood

Volumn 128, Issue 2, 2016, Pages 286-292

  Cooley, Brian ^a   Funkhouser, William ^a   Monroe, Dougald ^a   Ezzell, Ashley ^a   Mann, David M ^b   Lin, Feng Chang ^c   Monahan, Paul E ^a   Stafford, Darrel W ^d  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b Mann BioConsulting   (United States)

^c IL   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 4; RECOMBINANT BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9; FACTOR IX FC FUSION PROTEIN; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEEDING; BLOOD VESSEL; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; EXTRAVASCULAR SPACE; HEMOPHILIA B; HEMOSTASIS; HUMAN; HUMAN TISSUE; LIVER TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; SAPHENOUS VEIN; SMOOTH MUSCLE; THROMBOGENICITY; THROMBOSIS; TREATMENT RESPONSE; ANIMAL; BLOOD; DISEASE MODEL; DOSE RESPONSE; HEMORRHAGE;

ANIMALS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR IX; HEMOPHILIA B; HEMORRHAGE; IMMUNOGLOBULIN FC FRAGMENTS; MICE; RECOMBINANT FUSION PROTEINS;

EID: 84990057195     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-01-696104     Document Type: Article

References (38)

1. Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al; Treatment Guidelines Working Group on Behalf of The World Federation Of Hemophilia. Guidelines for the management of hemophilia. Haemophilia. 2013;19(1):e1-e47.
2. Jiménez-Yuste V, Auerswald G, Benson G, et al. Achieving and maintaining an optimal trough level for prophylaxis in haemophilia: the past, the present and the future. Blood Transfus. 2014;12(3):314-319.
3. Björkman S. Pharmacokinetics of plasma-derived and recombinant factor IX - implications for prophylaxis and on-demand therapy. Haemophilia. 2013;19(6):808-813.
4. Soucie M, Monahan P, Mazepa M, Kulkarni RP, Konkle BA. Hemophilia Treatment Center Network. Relations between factor activity level and joint bleeding in a large cohort of males with mild and moderate hemophilia in the United States [abstract]. J Thromb Haemost. 2015;13(Suppl 2). Abstract 157
5. Powell JS, Pasi KJ, Ragni MV, et al; B-LONG Investigators. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med. 2013;369(24):2313-2323.
6. Negrier C, Knobe K, Tiede A, Giangrande P, Møss J. Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B. Blood. 2011;118(10):2695-2701.
7. Martinowitz U, Lissitchkov T, Lubetsky A, et al. Results of a phase I/II open-label, safety and efficacy trial of coagulation factor IX (recombinant), albumin fusion protein in haemophilia B patients. Haemophilia. 2015;21(6):784-790.
8. Cheung WF, van den Born J, Kühn K, Kjellén L, Hudson BG, Stafford DW. Identification of the endothelial cell binding site for factor IX. Proc Natl Acad Sci USA. 1996;93(20):11068-11073.
9. Gui T, Reheman A, Ni H, et al. Abnormal hemostasis in a knock-in mouse carrying a variant of factor IX with impaired binding to collagen type IV. J Thromb Haemost. 2009;7(11):1843-1851.
10. Feng D, Stafford KA, Broze GJ, Stafford DW. Evidence of clinically significant extravascular stores of factor IX. J Thromb Haemost. 2013;11(12):2176-2178.
11. Stern DM, Knitter G, Kisiel W, Nawroth PP. In vivo evidence of intravascular binding sites for coagulation factor IX. Br J Haematol. 1987;66(2):227-232.
12. Lin HF, Maeda N, Smithies O, Straight DL, Stafford DW. A coagulation factor IX-deficient mouse model for human hemophilia B. Blood. 1997;90(10):3962-3966.
13. Pastoft AE, Lykkesfeldt J, Ezban M, Tranholm M, Whinna HC, Lauritzen B. A sensitive venous bleeding model in haemophilia A mice: effects of two recombinant FVIII products (N8 and Advate(®)). Haemophilia. 2012;18(5):782-788.
14. Cooley BC. In vivo fluorescence imaging of large-vessel thrombosis in mice. Arterioscler Thromb Vasc Biol. 2011;31(6):1351-1356.
15. Riera JR, Astengo-Osuna C, Longmate JA, Battifora H. The immunohistochemical diagnostic panel for epithelial mesothelioma: a reevaluation after heat-induced epitope retrieval. Am J Surg Pathol. 1997;21(12):1409-1419.
16. Gui T, Lin HF, Jin DY, et al. Circulating and binding characteristics of wild-type factor IX and certain Gla domain mutants in vivo. Blood. 2002;100(1):153-158.
17. Cheung WF, Hamaguchi N, Smith KJ, Stafford DW. The binding of human factor IX to endothelial cells is mediated by residues 3-11. J Biol Chem. 1992;267(29):20529-20531.
18. Schuettrumpf J, Herzog RW, Schlachterman A, Kaufhold A, Stafford DW, Arruda VR. Factor IX variants improve gene therapy efficacy for hemophilia B. Blood. 2005;105(6):2316-2323.
19. Janssen B, Debets J, Leenders P, Smits J. Chronic measurement of cardiac output in conscious mice. Am J Physiol Regul Integr Comp Physiol. 2002;282(3):R928-R935.
20. Mingozzi F, Schüttrumpf J, Arruda VR, et al. Improved hepatic gene transfer by using an adeno-associated virus serotype 5 vector. J Virol. 2002;76(20):10497-10502.
21. Peters RT, Low SC, Kamphaus GD, et al. Prolonged activity of factor IX as a monomeric Fc fusion protein. Blood. 2010;115(10):2057-2064.
22. Toomey JR, Smith KJ, Roberts HR, Stafford DW. The endothelial cell binding determinant of human factor IX resides in the gamma-carboxyglutamic acid domain. Biochemistry. 1992;31(6):1806-1808.
23. Robertson WE, Rose KL, Hudson BG, Vanacore RM. Supramolecular organization of the α121-α565 collagen IV network. J Biol Chem. 2014;289(37):25601-25610.
24. Seki T, Naito I, Oohashi T, Sado Y, Ninomiya Y. Differential expression of type IV collagen isoforms, alpha5(IV) and alpha6(IV) chains, in basement membranes surrounding smooth muscle cells. Histochem Cell Biol. 1998;110(4):359-366.
25. Pokidysheva E, Boudko S, Vranka J, et al. Biological role of prolyl 3-hydroxylation in type IV collagen. Proc Natl Acad Sci USA. 2014;111(1):161-166.
26. Lowe G. Factor IX and deep vein thrombosis. Haematologica. 2009;94(5):615-617.
27. van Hylckama Vlieg A, van der Linden IK, Bertina RM, Rosendaal FR. High levels of factor IX increase the risk of venous thrombosis. Blood. 2000;95(12):3678-3682.
28. Vandenbroucke JP, Koster T, Briët E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet. 1994;344(8935):1453-1457.
29. White GC II. Safety and recovery of mononine in multiple-dose, high-dose regimens. Acta Haematol. 1995;94(Suppl 1):53-57, discussion 57-58.
30. Warrier I, Kasper CK, White GC II, Shapiro AD, Bergman GE; The Mononine Study Group. Safety of high doses of a monoclonal antibody-purified factor IX concentrate. Am J Hematol. 1995;49(1):92-94.
31. Wessler S, Reiner L, Freiman DG, Reimer SM, Lertzman M. Serum-induced thrombosis. Studies of its induction, and evolution under controlled conditions in vivo. Circulation. 1959;20:864-874.
32. Lynch T, Weinstein M, Chang A, et al. FDA Summary of Basis of Approval Reference Number 96-1048. 1997.
33. Simioni P, Tormene D, Tognin G, et al. X-linked thrombophilia with a mutant factor IX (factor IX Padua). N Engl J Med. 2009;361(17):1671-1675.
34. Pomp ER, Lenselink AM, Rosendaal FR, Doggen CJ. Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study. J Thromb Haemost. 2008;6(4):632-637.
35. Hoffman M, Colina CM, McDonald AG, Arepally GM, Pedersen L, Monroe DM. Tissue factor around dermal vessels has bound factor VII in the absence of injury. J Thromb Haemost. 2007;5(7):1403-1408.
36. Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am J Pathol. 1989;134(5):1087-1097.
37. Flood VH, Schlauderaff AC, Haberichter SL, et al; Zimmerman Program Investigators. Crucial role for the VWF A1 domain in binding to type IV collagen. Blood. 2015;125(14):2297-2304.
38. Kavakli K, Smith L, Kuliczkowski K, et al. Once-weekly prophylactic treatment vs. on-demand treatment with nonacog alfa in patients with moderately severe to severe haemophilia B [published online ahead of print January 29, 2016]. Haemophilia. doi:10.1111/hae.12878.